EN
中文 EN
Efficacy and safety of sintilimab plus anlotinib for PD-L1-positive recurrent, or metastatic cervical cancer: a multicenter, single arm, prospective phase II trial

Release date：January 08, 2784

Announcer：Burning Rock

Previous:

Next: Burning Rock Received Breakthrough Device Designation from China’s NMPA for its Multi-Cancer Early Detection Test

Recommended News
August 03, 2024
Development and validation of an integrated system for lungcancer screening and post-screening pulmonary nodulesmanagement: a proof-of-concept study (ASCEND-LUNG)
June 18, 2024
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: phase 2 trial interim results (NEOTIDE/CTONG2104)
February 19, 2024
Sintilimab with two cycles of chemotherapy for the treatment of advanced squamous non-small cell lung cancer: a phase 2 clinical trial
February 16, 2024
Unraveling the Significance of MET Focal Amplification in Lung Cancer: Integrative NGS, FISH, and IHC Investigation
Contact Our Experts
We would like to collect certain personal information about you through cookies and similar technologies in order to personalize the site for you, improve the performance of the site, and support our marketing efforts. By clicking “Accept All”, you confirm that we have your consent to collect and process your personal information in accordance with our Privacy Policy, which may include online targeted and social media advertising in some instances. You can by clicking “Reject All”, you can reject all cookies except for Strictly Necessary Cookies."